ChinaDaily Briefs

Daily Brief China: Swire Pacific (A), Sciclone Pharmaceuticals, Tencent, Sun Art Retail, Longfor Properties, West China Cement, WuXi AppTec, Taste Gourmet and more

In today’s briefing:

  • Swire Pac (19 HK): Flying High
  • SciClone Pharma (6600 HK): GL Capital Consortium Reload?
  • Tencent (700 HK): Gross Margins, Cost Cutting Likely to Be Focus Going into Q4 FY23 Results
  • SciClone Pharma (6600 HK): Privatisation Déjà Vu All over Again?
  • Sun Art (6808 HK):  Potential Divestiture By Alibaba Worth A Bet
  • Morning Views Asia: Adani Green Energy, Azure Power Global Ltd, Greenko Energy Holdings
  • Morning Views Asia: Adani Green Energy, Azure Power Global Ltd, Greenko Energy Holdings
  • West China Cement – Earnings Flash – FY 2023 Results – Lucror Analytics
  • WuXi AppTec (2359.HK/603259.CH) 2023 Results – Time to Prepare for the Worst
  • Taste Gourmet (8371 HK): Earnings Preview FY24


Swire Pac (19 HK): Flying High

By David Blennerhassett


SciClone Pharma (6600 HK): GL Capital Consortium Reload?

By David Blennerhassett

  • A little over a year ago, shareholders approved Sciclone Pharmaceuticals (6600 HK)‘s buyback, which lifted GL Capital’s holding to 31.63% from 28.09%, enabling creep provisions.
  • After the share price gained 14% yesterday, SciClone was suspended pursuant to the Code on Takeovers and Mergers before trading commenced this morning. Mmm.
  • GL Capital, together with CDH Investments, Ascendent Capital Partner, Ocean Falcon Limited, and Boying Investments Limited, took SciClone private in 2017. Time for another privatisation?

Tencent (700 HK): Gross Margins, Cost Cutting Likely to Be Focus Going into Q4 FY23 Results

By Charlotte van Tiddens, CFA

  • Tencent is due to release FY23 results tomorrow morning after the HK close. The earnings call is scheduled for 14:00 SAST.
  • The market is expecting 1.8% QoQ revenue growth, 8.6% YoY. Strong QoQ revenue growth of 10% is expected for the advertising segment.
  • QoQ revenue growth for the gaming sector is expected to decline by 4.9%. Domestic gaming revenue is expected to fall by 7.6%, international gaming revenue expected to increase by 9.6%.

SciClone Pharma (6600 HK): Privatisation Déjà Vu All over Again?

By Arun George

  • After rising 14% on Monday, Sciclone Pharmaceuticals (6600 HK) entered a trading halt “pending the release of an announcement pursuant to the Code on Takeovers and Mergers.
  • SciClone US was listed on NASDAQ in March 1992 and was privatised in October 2017 by a GL Capital-led consortium. It was relisted on the HKEx on 3 March 2021.
  • A GL Capital-led consortium will likely once again lead the privatisation. An offer price at or slightly above the IPO price (HK$18.80) would be sufficient to get the vote up.

Sun Art (6808 HK):  Potential Divestiture By Alibaba Worth A Bet

By Steve Zhou, CFA

  • According to public news two days ago, COFCO Group is rumored to be a potential suitor for Alibaba’s 78% stake in Sun Art Retail (6808 HK).
  • Alibaba wants to eventually get rid of the Sun Art stake, especially after Alibaba’s management change in late 2023.  
  • Given limited downside, I believe it is worth a bet on the uncertain timeline but certain intention of the eventual divestiture of Sun Art by Alibaba.

Morning Views Asia: Adani Green Energy, Azure Power Global Ltd, Greenko Energy Holdings

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Morning Views Asia: Adani Green Energy, Azure Power Global Ltd, Greenko Energy Holdings

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


West China Cement – Earnings Flash – FY 2023 Results – Lucror Analytics

By Leonard Law, CFA

West China Cement’s (WCC) FY 2023 results were soft, but in line with expectations. The company’s profitability in Mainland China continued to weaken, albeit this was partly offset by rising sales volumes and ASP from its African operations. As a result, operating profit in Africa climbed above that for Mainland China for the first time, with the African segment accounting for 31% of total revenue and 74% of operating profit.

In our view, the key risk for investors is WCC’s seemingly relentless expansion in Africa, which is likely to further weaken its leverage. Moreover, we are concerned that further expansion in this region will fundamentally change WCC’s risk profile from a relatively stable infrastructure-led Chinese business to one that is highly exposed to event risks in frontier markets. The company’s African businesses could be exposed to higher geopolitical, regulatory and ESG risks, which are less well understood by investors.


WuXi AppTec (2359.HK/603259.CH) 2023 Results – Time to Prepare for the Worst

By Xinyao (Criss) Wang

  • WuXi AppTec’s 2023 results were disappointing. The decline in performance in 23H2 was quite severe. 2024 performance guidance could be meaningless because the biggest concern now is the geopolitical conflicts.
  • If the bill is passed, valuation logic would completely change – not based on DCF/PE, but on PB, market value falling below RMB100 billion. We cannot rule out another privatisation.
  • We hope that WuXi AppTec can prepare contingency plans for the worst-case scenario that may occur, rather than simply denying or mitigating the impact of BIOSECURE Act on the Company

Taste Gourmet (8371 HK): Earnings Preview FY24

By Sameer Taneja

  • Taste Gourmet (8371 HK) will report its FY24 results in the third week of June. We estimate revenue/earnings growth of 38%/40% YoY. 
  • We expect the company to end FY24 with >180 mn HKD of net cash on the balance sheet, representing 32% of the mkt cap (9MFY23 cash 148 mn HKD)
  • Maintaining a 50% dividend payout ratio, we expect the company to declare a final DPS of 7 cents ( H1FY24 5.5 cents HKD), representing an 8.5% yield for FY24

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars